-
NeuroSense’s PrimeC Shows Remarkable 65% Reduction in ALS Mortality Risk and Over 14-Month Survival Extension
NASDAQ: $NRSN NeuroSense Therapeutics Ltd., a biotechnology company concentrating on developing treatments for neurodegenerative conditions, has recently released compelling long-term survival data from its completed PARADIGM Phase 2b clinical trial assessing PrimeC for amyotrophic lateral sclerosis (ALS). This extended analysis confirms a clinically significant and statistically robust improvement in overall survival for patients treated with…
-
SOPHiA GENETICS Expands U.S. Footprint with Agreements with Two Major Integrated Health Systems
NASDAQ: $SOPH SOPHiA GENETICS, a recognized leader in AI-driven precision medicine, has significantly augmented its presence in the United States through agreements with two substantial, integrated healthcare systems. This expansion marks a pivotal moment in bringing advanced genomic analysis to a wider patient population across key regions. These two newly integrated institutions represent some of…
-
Viking Therapeutics Announces Q4 and Full-Year 2025 Financial Results Date
NASDAQ: $VKTX Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and endocrine diseases, has officially announced the date for its upcoming financial report. Investors and interested parties can anticipate the company’s financial results for the fourth quarter and the full year ended December 31, 2025, which will be released…
-
Rigel Strengthens Leadership with Appointment of Michael P. Miller to Board of Directors
NASDAQ: $RIGL Rigel Pharmaceuticals, Inc. recently announced a significant addition to its leadership structure with the appointment of Michael P. Miller to its Board of Directors, effective immediately. Mr. Miller brings a wealth of experience in the biotechnology and pharmaceutical sectors, promising to contribute valuable strategic insights as Rigel continues to advance its pipeline and…
-
Avidity Biosciences Sets Record Date for Potential Spin-Off of RNA Therapeutics Business
NASDAQ: $RNA Avidity Biosciences, Inc. has recently announced a significant corporate development concerning its RNA therapeutics business. The company has established an expected record date for the potential separation of its RNA therapeutics business into an independent, publicly traded entity. The Potential Spin-Off Explained In a move designed to potentially maximize shareholder value and allow…
-
ADC Therapeutics Strengthens Team with New Employee Inducement Grants
NYSE: $ADCT ADC Therapeutics SA, a commercial-stage, late-stage biotechnology company focused on the development and commercialization of antibody drug conjugates (ADCs) for patients suffering from cancer, recently announced a significant commitment to its growing workforce. In a filing dated December 17, 2024, the company disclosed the granting of equity awards to newly hired employees under…
-
Anixa Biosciences Advances CAR-T Therapy with U.S. Adopted Name Approval
NASDAQ: $ANIX Anixa Biosciences, Inc., a biotechnology company focused on the development of innovative cancer therapies, has reached a significant milestone in the progression of its CAR-T cell therapy candidate. The company announced that the United States Adopted Names (USAN) Council has approved the non-proprietary name for its novel CAR-T therapy. This approval of a…
-
Edgewise Therapeutics Announces Inducement Grants Under Nasdaq Rules
NASDAQ: $EWTX Edgewise Therapeutics Reports Inducement Grants as Permitted by Nasdaq Listing Rules Edgewise Therapeutics, Inc., a company focused on developing transformative therapies for muscular dystrophies, has recently announced the issuance of new equity awards. These grants were made as inducement awards to newly hired non-executive employees, a practice fully compliant with the Nasdaq Stock…